(4R)-3-[4-(6-amino-5-bromo-3-pyridinyl)cyclohexyl]-5,5-dimethyl-4-phenyl-1,3-oxazolidin-2-one;(4R)-3-[4-[6-amino-5-(pyrimidin-2-ylamino)-3-pyridinyl]cyclohexyl]-5,5-dimethyl-4-phenyl-1,3-oxazolidin-2-one;(4R)-5,5-dimethyl-3-[4-(2-oxo-1-pyrimidin-2-yl-3H-imidazo[4,5-b]pyridin-6-yl)cyclohexyl]-4-phenyl-1,3-oxazolidin-2-one;pyrimidin-2-amine
C79H89BrN18O7 — CID 159864021
Data last refreshed: (MolForge compound catalog, from PubChem)
About (4R)-3-[4-(6-amino-5-bromo-3-pyridinyl)cyclohexyl]-5,5-dimethyl-4-phenyl-1,3-oxazolidin-2-one;(4R)-3-[4-[6-amino-5-(pyrimidin-2-ylamino)-3-pyridinyl]cyclohexyl]-5,5-dimethyl-4-phenyl-1,3-oxazolidin-2-one;(4R)-5,5-dimethyl-3-[4-(2-oxo-1-pyrimidin-2-yl-3H-imidazo[4,5-b]pyridin-6-yl)cyclohexyl]-4-phenyl-1,3-oxazolidin-2-one;pyrimidin-2-amine
(4R)-3-[4-(6-amino-5-bromo-3-pyridinyl)cyclohexyl]-5,5-dimethyl-4-phenyl-1,3-oxazolidin-2-one;(4R)-3-[4-[6-amino-5-(pyrimidin-2-ylamino)-3-pyridinyl]cyclohexyl]-5,5-dimethyl-4-phenyl-1,3-oxazolidin-2-one;(4R)-5,5-dimethyl-3-[4-(2-oxo-1-pyrimidin-2-yl-3H-imidazo[4,5-b]pyridin-6-yl)cyclohexyl]-4-phenyl-1,3-oxazolidin-2-one;pyrimidin-2-amine (PubChem CID 159864021) has the molecular formula C79H89BrN18O7 and a molecular weight of 1482.60 g/mol. Its IUPAC name is (4R)-3-[4-(6-amino-5-bromo-3-pyridinyl)cyclohexyl]-5,5-dimethyl-4-phenyl-1,3-oxazolidin-2-one;(4R)-3-[4-[6-amino-5-(pyrimidin-2-ylamino)-3-pyridinyl]cyclohexyl]-5,5-dimethyl-4-phenyl-1,3-oxazolidin-2-one;(4R)-5,5-dimethyl-3-[4-(2-oxo-1-pyrimidin-2-yl-3H-imidazo[4,5-b]pyridin-6-yl)cyclohexyl]-4-phenyl-1,3-oxazolidin-2-one;pyrimidin-2-amine.
Molecular Properties
| Compound Name | (4R)-3-[4-(6-amino-5-bromo-3-pyridinyl)cyclohexyl]-5,5-dimethyl-4-phenyl-1,3-oxazolidin-2-one;(4R)-3-[4-[6-amino-5-(pyrimidin-2-ylamino)-3-pyridinyl]cyclohexyl]-5,5-dimethyl-4-phenyl-1,3-oxazolidin-2-one;(4R)-5,5-dimethyl-3-[4-(2-oxo-1-pyrimidin-2-yl-3H-imidazo[4,5-b]pyridin-6-yl)cyclohexyl]-4-phenyl-1,3-oxazolidin-2-one;pyrimidin-2-amine |
|---|---|
| PubChem CID | 159864021 |
| Molecular Formula | C79H89BrN18O7 |
| Molecular Weight | 1482.60 g/mol |
| Exact Mass | 1480.63 |
| IUPAC Name | (4R)-3-[4-(6-amino-5-bromo-3-pyridinyl)cyclohexyl]-5,5-dimethyl-4-phenyl-1,3-oxazolidin-2-one;(4R)-3-[4-[6-amino-5-(pyrimidin-2-ylamino)-3-pyridinyl]cyclohexyl]-5,5-dimethyl-4-phenyl-1,3-oxazolidin-2-one;(4R)-5,5-dimethyl-3-[4-(2-oxo-1-pyrimidin-2-yl-3H-imidazo[4,5-b]pyridin-6-yl)cyclohexyl]-4-phenyl-1,3-oxazolidin-2-one;pyrimidin-2-amine |
| SMILES | CC1(C)OC(=O)N(C2CCC(c3cnc(N)c(Br)c3)CC2)[C@@H]1c1ccccc1.CC1(C)OC(=O)N(C2CCC(c3cnc(N)c(Nc4ncccn4)c3)CC2)[C@@H]1c1ccccc1.CC1(C)OC(=O)N(C2CCC(c3cnc4[nH]c(=O)n(-c5ncccn5)c4c3)CC2)[C@@H]1c1ccccc1.Nc1ncccn1 |
| InChI | InChI=1S/C27H28N6O3.C26H30N6O2.C22H26BrN3O2.C4H5N3/c1-27(2)22(18-7-4-3-5-8-18)32(26(35)36-27)20-11-9-17(10-12-20)19-15-21-23(30-16-19)31-25(34)33(21)24-28-13-6-14-29-24;1-26(2)22(18-7-4-3-5-8-18)32(25(33)34-26)20-11-9-17(10-12-20)19-15-21(23(27)30-16-19)31-24-28-13-6-14-29-24;1-22(2)19(15-6-4-3-5-7-15)26(21(27)28-22)17-10-8-14(9-11-17)16-12-18(23)20(24)25-13-16;5-4-6-2-1-3-7-4/h3-8,13-17,20,22H,9-12H2,1-2H3,(H,30,31,34);3-8,13-17,20,22H,9-12H2,1-2H3,(H2,27,30)(H,28,29,31);3-7,12-14,17,19H,8-11H2,1-2H3,(H2,24,25);1-3H,(H2,5,6,7)/t2*17?,20?,22-;14?,17?,19-;/m111./s1 |
| InChIKey | NRMVQGSHVMHSSV-BPOFIDJCSA-N |
| XLogP | 15.18 |
| TPSA | 332.51 Ų |
| H-Bond Donors | 5 |
| H-Bond Acceptors | 21 |
| Rotatable Bonds | 12 |
| Heavy Atoms | 105 |
| Complexity | — |
Lipinski Rule of Five
3 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 1482.60 |
| LogP ≤ 5 | 15.18 |
| H-Bond Donors ≤ 5 | 5 |
| H-Bond Acceptors ≤ 10 | 21 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': '>_2_ester_groups', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 159864021 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.